Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?

Warren Buffett has grown his empire by buying great companies. The CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing the exact same thing. Could that make him the next Buffett?

| More on:
The Motley Fool

One thing that Warren Buffett does very well is buy businesses. With the amount of capital that he has available to him through Berkshire Hathaway Inc., he can go out and buy out an entire company without blinking an eye.

And then when he does buy these companies, he is able to integrate them into the overall structure, and take the cash flow they provide to make even larger investments. This is how Buffett went from buying stocks—which he still does to an extent—to outright buying businesses.

Believe it or not, J. Michael Pearson, the CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing something quite similar. And Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant could be this generation’s Berkshire.

Ackman has invested 20% of his funds into Valeant. The reason he believes that he is holding a large stake in the next Berkshire is because of how many acquisitions Valeant makes every year. He views the company as a “platform company,” meaning it buys other companies to increase its own value. Instead of launching organic projects, it just buys them. That sounds a lot like Berkshire to me.

Over the past seven years Valeant has acquired over 100 businesses. And according to Ackman, they’ve been integrated into the larger organization rather seamlessly. If Pearson is good at one thing, it’s finding efficiency when combining companies.

Why this matters to you

Valeant isn’t slowing down. The company is going to continue buying other firms—large and small—with the goal of increasing its size. That’s how Berkshire works and that’s likely how Valeant is going to continue to work over the coming years.

This matters to you because platform companies are perpetually undervalued. Ackman has two examples to back this up. When the company bought Bausch & Lomb, the stock was valued at $74. The announcement of its agreement to buy made the price jump to $95. When it agreed to buy Salix Pharmaceuticals, the stock jumped from $217 to $250.

Now, there’s no denying that this stock has been on a meteoric rise. And Ackman’s belief is that the company will continue to make acquisitions in the $7-20 billion range every year. Pearson is not looking to create just another company; he wants to build a behemoth. And his strategy is to follow in the footsteps of the greatest investor of all time: Warren Buffett.

All of this, however, doesn’t immediately warrant a buy. Valeant is risky. It has a lot of debt and it doesn’t pay a penny in dividends to investors. Therefore, what you’re hoping for is a continuous rise in the price per share. In the event that the market corrects, this stock will drop because all stocks will drop.

But long term, if Pearson is successful and if Ackman can correctly predict the undervaluation of platform companies, then this stock will reward investors handsomely.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Growing plant shoots on coins
Stocks for Beginners

2 TSX Growth Stocks That Could Turn $10,000 Into $23,798 by 2030

Are you looking for growth stocks? These two are proven winners with even more room to grow in the years…

Read more »

Senior Couple Walking With Pet Bulldog In Countryside
Dividend Stocks

Canadian Retirees: 2 Top Dividend Stocks for Tax-Free Passive Income

When establishing a reliable dividend income that can sustain you through retirement, it's usually smart to stick to Aristocrats with…

Read more »

money cash dividends
Dividend Stocks

My Top Dividend Pick for 2024 Is a Passive-Income Powerhouse

Energy is back as TSX’s top-performing sector and one passive-income powerhouse is a top pick for dividend investors.

Read more »

Investor wonders if it's safe to buy stocks now
Stocks for Beginners

Underpriced and Overlooked: 2 Canadian Stocks Ready to Rally

Momentum is underway for these two Canadian stocks, and yet both still trade at share prices that are quite low…

Read more »

dividends grow over time
Dividend Stocks

Have $75,000 to Invest? Make an Average of $100/Week Tax-Free

If you have cash to invest in your TFSA, these two high-yield dividend stocks are some of the best passive-income…

Read more »

TELECOM TOWERS
Dividend Stocks

Better Telecom Buy: Telus Stock or BCE?

Take a closer look at these two top TSX telecom stocks to determine which might be a better investment right…

Read more »

grow dividends
Dividend Stocks

BCE Stock Needs to Cut Its Dividend – Now

BCE stock (TSX:BCE) has seen shares fall drastically with more debt rising, so why on earth did it increase its…

Read more »

consider the options
Dividend Stocks

Is Now the Right Time to Buy goeasy Stock? Here’s My Take

Is now the time to buy goeasy stock?

Read more »